Predictors of response to systemic therapy in breast cancer

FORUM - Trends in Experimental and Clinical Medicine

Volumn 12, Issue 1, 2002, Pages 19-32

  Ring, Alistair E ^a   Ellis, Paul A ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Predictive factors; Systemic therapy

Indexed keywords

ALKYLATING AGENT; ANTIESTROGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; DROLOXIFENE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FADROZOLE; FLUOROURACIL; GEFITINIB; GOSERELIN; KI 67 ANTIGEN; LETROZOLE; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; ONCOPROTEIN; PACLITAXEL; PEMETREXED; PREDNISOLONE; PROGESTERONE RECEPTOR; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB;

BIOLOGICAL THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL CYCLE S PHASE; CLINICAL TRIAL; DNA MICROARRAY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENE EXPRESSION PROFILING; HORMONAL THERAPY; HUMAN; INDIVIDUALIZATION; MOLECULAR GENETICS; ONCOGENE NEU; PLOIDY; PREDICTION; REVIEW; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENES, ERBB-1; GENES, P53; HUMANS; KI-67 ANTIGEN; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0037003612     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Hamilton A and Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann. Oncol. 2000; 11: 647-663.
2. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 1998; 51: 227-238.
3. Jaiyesimi IA et al. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 1995; 13: 513-529.
4. Ingle JN et al. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 1991; 68: 34-39.
5. Paridaens R et al. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 1980; 46 (Suppl. 12): 2889-2895.
6. Campbell FC et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981; ii: 1317-1319.
7. Lippman ME and Allegra JC. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 1980; 46 (Suppl. 12): 2829-2834.
8. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451-1467.
9. Horowitz KB and McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189: 726-727.
10. Ravdin PM et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 1992; 10: 1284-1291.
11. Stewart J et al. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res. Treat. 1982; 2: 243-250.
12. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
13. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
14. Liu Y et al. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res. Treat. 1995; 34: 97-117.
15. Carlomagno C et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 1996; 14: 2702-2708.
16. Bianco AR DLM et al. HER2 overexpression predicts adjuvant tamoxifen failure for early breast cancer: Complete data at 20 years of the Naples GUN randomised trial. Proc. Am. Soc. Clin. Oncol. 2000; (abs. 289).
17. Berry DA et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J. Clin. Oncol. 2000; 18: 3471-3479.
18. Knoop AS et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J. Clin. Oncol. 2001; 19: 3376-3384.
19. Tetu B and Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node- positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359-2365.
20. Sjogren S et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. Clin. Oncol. 1998; 16: 462-469.
21. Giai M et al. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anti-cancer Res. 1994; 14: 1441-1450.
22. Dowsett M et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001; 61: 8452-8458.
23. Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor- positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 2001; 19: 3808-3816.
24. Lipton A et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol. 2002; 20: 1467-1472.
25. Houston SJ et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer 1999; 79: 1220-1226.
26. Elledge RM et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin. Cancer Res. 1998; 4: 7-12.
27. Yamauchi H et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol. 1997; 15: 2518-2525.
28. Archer SG et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer 1995; 72: 1259-1266.
29. Leitzel K et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 1995; 13: 1129-1135.
30. Berns EM et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995; 159: 11-18.
31. Nicholson RI et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur. J. Cancer 1993; 7: 1018-1023.
32. Wright C et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 1992; 65: 118-121.
33. Nicholson S et al. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989; i: 182-185.
34. Bouzubar N et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br. J. Cancer 1989; 59: 943-947.
35. Kenny FS et al. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res. Treat. 2001; 65: 135-144.
36. Chang J et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin. Cancer Res. 2000; 6: 616-621.
37. Geisler J et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin. Cancer Res. 2001; 7: 1230-1236.
38. Nicholson RI et al. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur. J. Cancer 1991; 27: 908-913.
39. Lowe SW et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
40. Perry RR et al. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. Surg. Oncol. 1995; 2: 238-245.
41. Elledge RM et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J. Clin. Oncol. 1997; 15: 1916-1922.
42. Makris A et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res. 1997; 3: 593-600.
43. Berns EM et al. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J. Clin. Oncol. 1998; 16: 121-127.
44. Bergh J et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1995; 1: 1029-1034.
45. Silvestrini R et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol. 1996; 14: 1604-1610.
46. Fisher CJ et al. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br. J. Cancer 1994; 69: 26-31.
47. Bonnefoi H et al. p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br. J. Cancer 2002; 86: 750-755.
48. Hartmann A et al. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet. 1997; 13: 27-33.
49. Gasparini G et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. 1995; 1: 189-198.
50. Hurlimann J et al. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch. 1995; 426: 163-168.
51. Long B et al. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br. J. Cancer 1992; 65: 865-869.
52. Maasarweh S SJ et al. Inhibition of epidermal growth factor/HER2 receptor signalling using ZD1839 ("Iressa") restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumours. Proc. Am. Soc. Clin. Oncol. 2002; (abs. 130).
53. Kiang DT et al. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N. Engl. J. Med. 1978; 299: 1330-1334.
54. Lippman ME et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 1978; 298: 1223-1228.
55. Cole BF et al. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001; 358: 277-286.
56. Coates AS et al. Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet 1998; 352: 1783-1784.
57. Colleoni M et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur. J. Cancer 1999; 35: 574-579.
58. Colleoni M et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann. Oncol. 2000; 11: 1057-1059.
59. Van Poznak C et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J. Clin, Oncol. 2002; 20: 2319-2326.
60. Allred DC et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 1992; 10: 599-605.
61. Gusterson BA et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol. 1992; 10: 1049-1056.
62. Miles DW et al. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int. J. Cancer 1999; 84: 354-359.
63. Menard S et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumour biologic variables. J. Clin. Oncol. 2001; 19: 329-335.
64. Stal O et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur. J. Cancer 1995; 31A: 2185-2190.
65. Mehta RR et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J. Clin. Oncol. 1998; 16: 2409-2416.
66. Doroshow JH SJ et al. Immunohistochemical and histopathologic factors predicting progression-free survival (PFS) and overall survival (OS) following high dose chemotherapy (HDCT) and stem cell rescue (SCR) for resposive metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 1996; (abs. 176).
67. Muss HB et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 1994; 330: 1260-1266.
68. Thor AD et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. 1998; 90: 1346-1360.
69. Paik S et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 1998; 90: 1361-1370.
70. Ravdin PM GS et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen alone. Proc. Am. Soc. Clin. Oncol. 1998; (abs. 374).
71. Niskanen E et al. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br. J. Cancer 1997; 76: 917-922.
72. Revillion F et al. Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. Eur. J. Cancer 1996; 32: 231-234.
73. Rozan S et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer 1998; 79: 27-33.
74. Vargas-Roig LM et al. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer 1999; 84: 129-134.
75. Pritchard KI OMF et al. Prognostic and predictive value of HER2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node positive breast cancer. Proc. Am. Soc. Clin. Oncol. 2002; (abs. 165).
76. Di Leo A LD et al. CMF or anthracycline-based adjuvant therapy for node positive breast cancer patients:4 year results of a Belgian randomised clinical trial with predictive marker analysis. Proc. Am. Soc. Clin. Oncol. 1999; (abs. 258).
77. Paik S et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J. Natl. Cancer Inst. 2000; 92: 1991-1998.
78. Baselga J et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 1997; 11 (3 Suppl. 2): 43-48.
79. Volm MD HY et al. HER2 status predicts response to preoperative paclitaxel in patients with breast cancer. Proc. Am. Soc. Clin. Oncol. 1999; (abs. 394).
80. Hamilton A et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin. Breast Cancer 2000; 1: 233-240; discussion 41-42.
81. Ellis PA et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res. Treat. 1998; 48: 107-116.
82. Chang J et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J. Clin. Oncol. 1999; 17: 3058-3063.
83. Makris A et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res. Treat. 1999; 53: 51-59.
84. Bottini A et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br. J. Cancer 2001; 85: 1106-1112.
85. Aas T et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996; 2: 811-814.
86. Chevillard S et al. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin. Cancer Res. 1997; 3: 2471-2478.
87. Mottolese M et al. Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J. Cancer Res. Clin. Oncol. 2000; 126: 722-729.
88. Bottini A et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin. Cancer Res. 2000; 6: 2751-2758.
89. Elledge RM et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. Natl. Cancer Inst. 1995; 87: 1254-1256.
90. Schmitt CA et al. A Senescence Program Controlled by p53 and p16(INK4a) Contributes to the Outcome of Cancer Therapy. Cell 2002; 109: 335-346.
91. van Slooten HJ et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br. J. Cancer 1996; 74: 78-85.
92. O'Reilly SM et al. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur. J. Cancer 1992; 28: 681-683.
93. Chevillard S et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neo-adjuvant chemotherapy. Cancer 1996; 77: 292-300.
94. Witzig TE et al. DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. J. Clin. Oncol. 1993; 11: 351-359.
95. Goldstein LJ et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J. Clin. Oncol. 1990; 8: 128-136.
96. van 't Veer LJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
97. Eifel P et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl. Cancer Inst. 2001; 93: 979-989.
98. Goldhirsch A et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J. Natl. Cancer Inst. 1998; 90: 1601-1608.
99. Lewis GD et al. Differential responses of human tumour cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 1993; 37: 255-263.
100. Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002; 20: 719-726.
101. Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344: 783-792.
102. Cobleigh MA et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999; 17: 2639-2648.
103. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001; 61 (Suppl. 2): 14-21.
104. Bast RC Jr et al. 2000 update of recommendations for the use of tumour markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001; 19: 1865-1878.
105. Albanell J et al. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 2001; 28 (5 Suppl. 16): 56-66.
106. Sirotnak FM et al. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000; 6: 4885-4892.
107. Di Marco E et al. Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 1989; 4: 831-838.
108. Salomon DS et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995; 19: 183-232.
109. Qi CF et al. Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br. J. Cancer 1994; 69: 903-910.
110. Normanno N et al. Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res. Treat. 1995; 35: 293-297.